IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Repros Therapeutics Inc

CUSIP: 76028H959 | 4 institutional holders

Quarters

Q2 2017Q4 2016Q3 2016Q2 2016Q1 2016
CompareDetailedHistoricalFundsOptionsShort Interest13D/13GPeersTargetingTrading SummaryProfile